Impact of Exercise Therapy on Functional Capacity in Patients Listed for Liver Transplantation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Birmingham, United Kingdom
- Queen Elizabeth University Hospital Birmingham
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meet the United Kingdom Liver Transplant criteria for listing
- Accepted on the liver transplant waiting list for a primary transplant
- Adults ≥18years who have an indication for a liver transplant
- Diagnosed with sarcopenia at liver transplant assessment
Exclusion Criteria:
- Significant cardiovascular instability including a recent Myocardial infarction, recent Cerebrovascular accident and/or a recent unstable arrhythmia
- Unstable encephalopathy - open to interpretation by the chief investigator
- Patient or next of kin non-English speaking
- Inpatients
- Refusal or lacks capacity to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention arm
12-week home prehabilitation program
|
12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with intervention-related adverse events as assessed by CTCAE v4.0
Time Frame: 12-week
|
As this is a feasibility/Pilot study the investigators need to assess if any participants have any adverse events related to the home prehabilitation programme and if so, determine the severity and frequency
|
12-week
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional capacity - incremental shuttle walk test
Time Frame: 12-weeks
|
incremental shuttle walk test
|
12-weeks
|
|
Functional capacity - short performance battery test
Time Frame: 12-weeks
|
12-weeks
|
|
|
Psychological wellbeing - HADS questionnaire
Time Frame: 12-weeks
|
HADS questionnaire
|
12-weeks
|
|
Quality of Life - EQ-5D questionnaire
Time Frame: 12-weeks
|
EQ-5D questionnaire
|
12-weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: James Ferguson, phD, Queen Elizabeth University Hospital Birmingham
- Principal Investigator: Felicity Williams, Queen Elizabeth University Hospital Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- QEUHB001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.